French health spend - 'no crisis, yet'

11 June 2006

The committee set up in France to issue warnings and impose economy measures if the country's health spending breaches pre-set limits has said there is no crisis, at least not at present. It is expected that, for the year 2006. overspending on health care will not exceed the legal limit of 0.75%, or equal to an amount of 1.0 billion euros ($1.28 billion).

However, the committee has said there is a risk and that, in order to respect the overall objective of health spending of 140.7 billion euros this year, the increase in reimbursement will have to be limited to 2.3% and not 2.5% as envisaged earlier. This would, in turn, require "quasi-stability" in the spending on general medical treatment which, despite moderate growth trends since January, appears unlikely.

Meanwhile, the Ministry of Health has said it accepts the expected impact of delaying the introduction of the new drug strategy and the slowdown in the number of prescriptions being issued, and will propose new measures later this month.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight